Recruiting
Sponsor ID
20250036
Efficacy, Safety and Tolerability of Switching from Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults with Obesity or Overweight (MARITIME-SWITCH)
Study Details
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Protocol Summary
Primary Outcome Measures
Percent Change from Baseline in Body Weight at Week 68
Timeframe: Week 68
Secondary Outcome Measures
Percent Change in Body Weight Prior to the Start of Weekly GLP-1RA at Week 68
Timeframe: Week 68
Percentage of Participants Maintaining ≥ 80% of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
Timeframe: Week 68
Percent Maintenance of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
Timeframe: Week 68
Plasma Concentration of Maridebart Cafraglutide at Week 68
Timeframe: Week 68
Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events
Timeframe: Up to 84 weeks
Locations
Location
Cahaba Research, Inc.
Pelham, AL, United States, 35124
Status
Recruiting
Location
Arizona Clinical Trials
Chandler, AZ, United States, 85224
Status
Recruiting
Location
North Georgia Clinical Research
Woodstock, GA, United States, 30189
Status
Recruiting
Location
Apex Clinical Research
San Diego, CA, United States, 92120
Status
Recruiting
Location
Progressive Medical Research
Port Orange, FL, United States, 32127
Status
Recruiting
Location
Clinical Neuroscience Solutions
Orlando, FL, United States, 32801
Status
Recruiting
Showing {first} - {last} of {total} Results